2026 NIAID DMID Omnibus Broad Agency Announcement
ID: HHS-NIH-NIAID-BAA2025-1Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/e1e43a392c2449e6805b9300906222a2/view
Timeline
    Description

    The Department of Health and Human Services, through the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: Research Area 001 focuses on developing therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, while Research Area 002 targets the creation of Direct Acting Antivirals for viruses of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases, with an estimated funding of $28.5 million available for awards in fiscal year 2026. Proposals for Research Area 001 are due by February 21, 2025, and for Research Area 002 by January 21, 2025; interested parties can contact Swee L. Teo at teosl@niaid.nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.

    Files
    Title
    Posted
    Attachment 14_PHS Human Subjects and Clinical Trials Information Form.docx
    The document outlines the requirements for the PHS Human Subjects and Clinical Trials Information, focusing on the submission of clinical trial data crucial for federal oversight. Key sections demand a unique study title, exemption status, and a clinical trial questionnaire that establishes if a study qualifies as a clinical trial based on criteria involving human participants, interventions, and health-related outcomes. It details the study population characteristics, such as conditions of study, eligibility criteria, and demographic inclusivity regarding women and minorities. Additionally, it emphasizes the necessity of recruitment strategies, study timelines, and inclusion enrollment reports, including the breakdown of enrollment demographics by race and ethnicity. Sections further elaborate on protections for human subjects, study design parameters, overall team structure, outcome measures, and any FDA-regulated interventions involved. Submission attachments for data protection, monitoring plans, and additional study materials are also part of the required documentation. The structure indicates a systematic approach to ensure compliance with federal regulations while advancing research in clinical trials.
    HHS-NIH-NIAID-BAA2024-1 - Amendment One.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) issued Amendment One to the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1 for the 2026 Division of Microbiology and Infectious Diseases (DMID) research initiatives. The solicitation focuses on developing therapeutics, vaccines, and diagnostics for antimicrobial-resistant pathogens and direct-acting antivirals for viruses with pandemic potential. Key proposal deadlines range from January 21 to February 21, 2025. The amendment provides responses to offeror questions and clarifies rules around foreign subcontractors and budget expectations, stating that NIAID estimates up to $20 million for funding three to four contracts in Research Area 002. It emphasizes that the contracts will be cost-reimbursement types with non-severable bases that do not exceed five years. Offerors must acknowledge receipt of the amendment, and a cut-off date for further questions is established. This document serves to facilitate understanding and compliance for potential contractors in the development of critical health interventions, reflecting NIAID’s initiative to advance public health research through open competition.
    HHS-NIH-NIAID-BAA2025-1.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals through a Broad Agency Announcement (BAA) focusing on the development of medical countermeasures to combat antimicrobial resistance and emerging infectious diseases. The BAA outlines two primary research areas for proposal submissions: Research Area 001 involves developing therapeutics, vaccines, and diagnostic tools for antimicrobial-resistant (AMR) bacterial and fungal pathogens, while Research Area 002 emphasizes the creation of Direct Acting Antivirals (DAA) for viruses of pandemic potential. The solicitation provides detailed technical objectives, eligibility criteria, and funding opportunities, estimating a combined total of $28.5 million for award in fiscal year 2026 across these areas. Proposals should showcase innovation and a robust plan for research that aligns with NIAID's broader strategies, including the National Biodefense Strategy and Pandemic Preparedness Plan. Each proposal will be evaluated based on its technical merit and the potential to address public health needs related to infectious diseases. Contract funding will support various phases from preclinical studies through early clinical trials, emphasizing expedited research and development processes.
    HHS-NIH-NIAID-BAA2025-1 - Amendment Five.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) issued Amendment Five to the 2026 DMID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1, effective January 10, 2025. The amendment clarifies responses to questions from potential offerors regarding research proposals focused on developing therapeutics, vaccines, and diagnostics against antimicrobial-resistant pathogens and direct acting antivirals for viral families with pandemic potential. Key proposal due dates vary by research area, with the first due on January 21, 2025, and the second by February 21, 2025. It specifies that contract research organizations are to be treated as subcontractors but provides no list of accepted vendors, placing responsibility on offerors for documentation and selection. The amendment reiterates that certain types of protein therapeutics are excluded and emphasizes that the BAA will culminate in a contract rather than a grant. Offerors must adhere to a minimum margin standard for proposal formats and include stage-appropriate Technical Product Profiles. The amendment underscores the competitive nature of the solicitation, maintaining the original solicitation’s terms and conditions while updating necessary information.
    HHS-NIH-NIAID-BAA2025-1 - Amendment Four.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) issued Amendment Four to the 2026 DMID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1, effective December 27, 2024. This amendment provides responses to questions pertaining to the solicitation, which encourages proposals in two research areas: the development of therapeutics for antimicrobial-resistant pathogens and direct antiviral agents for pandemic-prone viruses, with deadlines for proposal submission on February 21 and January 21, 2025, respectively. Key inquiries addressed include budget guidelines related to travel and training costs, the submission process for Small Business Subcontracting Plans, and specifications for bibliographies and optional proposals. The amendment emphasizes that responses are non-modifying and reiterates the competitive nature of the BAA, highlighting that no technical guidance will be provided regarding specific proposals. Notably, various projects must adhere to strict eligibility criteria and proposal submission rules, including time commitments for investigators involved in other federal projects. This BAA is critical for advancing research in combating infectious diseases and promoting public health initiatives.
    HHS-NIH-NIAID-BAA2025-1 - Amendment Six.pdf
    The document presents Amendment Six to the National Institute of Allergy and Infectious Diseases (NIAID) 2026 DMID Omnibus Broad Agency Announcement (BAA), identified as HHS-NIH-NIAID-BAA2025-1. Issued on January 16, 2025, this amendment updates the proposal due date for Research Area 001 to February 21, 2025, while the date for Research Area 002 remains January 21, 2025. The document outlines two primary research areas focused on developing therapeutics and diagnostics for antimicrobial-resistant pathogens and direct acting antivirals for pandemics. Key points include the need for offerors to acknowledge receipt of this amendment, the cut-off dates for submitting questions, and guidance on proposal submission requirements. The amendment also contains the government's responses to various questions posed by potential offerors, offering clarification on proposal formats. Overall, the purpose of this amendment is to provide updates and guidance while maintaining the integrity and continuity of the original solicitation.
    HHS-NIH-NIAID-BAA2025-1 - Amendment Three.pdf
    The National Institute of Allergy and Infectious Diseases (NIAID) has issued Amendment Three to its 2026 DMID Omnibus Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1, which outlines amendments regarding proposals for two main research areas: the development of therapeutics for antimicrobial-resistant pathogens and direct-acting antivirals for virus families potentially causing pandemics. Proposal due dates remain unchanged for each area. The amendment addresses queries from potential offerors about the solicitation, providing clarification on proposal components such as budget details, sample types, and specific technical requirements for submissions. It emphasizes that the proposals should be well-structured and adhere to the guidelines laid out in the solicitation, particularly regarding financial documentation and the inclusion of work plans. Importantly, it reminds offerors that the final decision on awards will hinge on evaluations based on the government’s evaluations and the availability of funds, and that costs incurred prior to contract award cannot be reimbursed. This document highlights NIAID's intention to support innovative solutions to pressing public health challenges while ensuring adherence to federal contracting protocols.
    HHS-NIH-NIAID-BAA2025-1 - Amendment Two.pdf
    The National Institute of Allergy & Infectious Diseases (NIAID) has issued Amendment Two to the Broad Agency Announcement (BAA) for the 2026 DMID Omnibus. This amendment clarifies proposal submission guidelines and adds responses to questions concerning the solicitation. Proposals for two research areas are highlighted: one focusing on developing therapeutics and diagnostics for antimicrobial-resistant pathogens due by February 21, 2025, and the other on direct-acting antivirals for viruses of pandemic potential due by January 21, 2025. Terms and conditions remain unchanged, and acknowledgments of the amendment are mandatory. Key questions addressed include clarifications on proposal content, eligibility for diversity among principal investigators, and issues regarding intellectual property rights for awardees. The responses aim to guide prospective offerors in their proposals but do not provide specific technical direction due to the BAA's competitive nature. The document reflects the NIAID's commitment to fostering innovative research while maintaining rigorous proposal standards.
    Pre-solicitation Notice - BAA2025-1 Final.pdf
    The 2026 NIAID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks proposals for research to enhance medical countermeasures against infectious diseases. NIAID, under the NIH, is soliciting innovative projects in two main research areas. Research Area 001 focuses on therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens. It comprises three topics: developing therapeutics for severe infections caused by specified pathogens, advancing vaccine candidates against ESKAPE bacterial pathogens, and creating diagnostic technologies for identifying fungal infections. Research Area 002 emphasizes the development of direct acting antivirals targeting viruses with pandemic potential, requiring proposals for new chemical entities that reduce viral load in early disease stages. Funding estimates range from $8.5 million for Research Area 001 to $20 million for Research Area 002, with expectations of one to two and three to four awards, respectively, each contract lasting up to five years. Proposals will be evaluated independently based on technical objectives set by the NIAID, with no guarantee of contract awards. Submission guidelines mandate online proposals via the NIAID electronic platform, with no provision for acceptance through email or fax. The announcement will be available around November 22, 2024, signaling the government's commitment to advancing public health through innovative research.
    Lifecycle
    Title
    Type
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Currently viewing
    Solicitation
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Presolicitation
    Similar Opportunities
    FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY26 Broad Agency Announcement (BAA) for advanced research and development in regulatory science. This opportunity aims to acquire basic and applied research that supports regulatory science and innovation, focusing on areas such as New Approach Methodologies, Advanced Manufacturing, and Clinical Outcome Assessments, among others. The FDA's initiative is crucial for enhancing scientific knowledge that aids in protecting and promoting public health, particularly for underrepresented populations and in reducing animal testing. Interested parties, including small businesses and academic institutions, are encouraged to submit proposals by February 24, 2026, and can reach out to Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative research to enhance public health preparedness against various biomedical threats. The initiative encompasses multiple Areas of Interest (AOIs), including the development of medical countermeasures for emerging infectious diseases, repurposing existing drugs for chemical threats, and advancing technologies for at-home diagnostics. Interested parties must have active registration with SAM.gov and are encouraged to engage in pre-submission consultations; abstract submissions are due by specified deadlines, with funding amounts contingent on the quality of proposals and alignment with program goals. For further inquiries, interested vendors can contact the BARDA DCMA DRIVe Team at DRIVeAcquisitions@hhs.gov.
    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking qualified contractors to support the development of vaccine medical countermeasures for pandemic influenza preparedness and response. The objective of this Sources Sought Notice (SSN) is to refine requirements and establish long-term partnerships with contractors capable of producing vaccines, antigens, and adjuvants necessary for pandemic preparedness and public health emergencies. This initiative is critical for enhancing the U.S. response to influenza viruses with pandemic potential and ensuring rapid regulatory decisions and manufacturing readiness. Interested parties must submit evidence of eligibility, capabilities statements, and requests to participate by email to Laura Saddison at Laura.Saddison@hhs.gov by 3:00 pm EST on December 19, 2025. This SSN/RFI is for information and planning purposes only and does not constitute a solicitation.
    Biological Technologies
    Dept Of Defense
    The Defense Advanced Research Projects Agency (DARPA) is soliciting proposals for its Biological Technologies Office (BTO) under Broad Agency Announcement HR001126S0003, aimed at leveraging biological properties and processes to enhance the protection of U.S. warfighters. The BAA invites innovative research proposals that focus on various areas, including biological and chemical technologies for national security, AI/ML applications, combat casualty care, and environmental solutions, with a clear exclusion of evolutionary improvements to existing practices. Proposals will be evaluated based on scientific merit, relevance to DARPA's mission, and cost realism, with multiple award types anticipated, including contracts and cooperative agreements, and an accelerated award option available for proposals under $2 million. Interested parties should submit abstracts and proposals on a rolling basis until September 30, 2026, and can contact the BAA Coordinator at BTOBAA2026@darpa.mil for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking proposals for extramural biomedical research and development. This opportunity is issued by the DEFENSE HEALTH AGENCY (DHA) under the BROAD AGENCY ANNOUNCEMENT (BAA) HT9425-23-S-SOC1. The purpose of this BAA is to solicit research and development ideas to advance the state-of-the-art or increase knowledge in the field. The projects funded under this BAA should focus on basic and applied research rather than the development of specific systems or hardware solutions. The research and development funding is expected to benefit both military and civilian medical practice and knowledge. Interested parties must submit a pre-proposal through the electronic Biomedical Research Application Portal (eBRAP). If selected, the offeror will be invited to submit a full proposal or application through Grants.gov. The BAA is open for a 5-year period, from August 1, 2023, to July 31, 2028. The BAA with revised research areas of interest and General Submission Instructions can be found on Grants.gov using opportunity number HT9425-23-S-SOC1.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1
    Dept Of Defense
    The Department of Defense, through the United States Special Operations Command (USSOCOM), is soliciting proposals for the Broad Agency Announcement (BAA) focused on Extramural Biomedical and Human Performance Research and Development, which will be open from August 1, 2023, to July 31, 2028. This initiative aims to enhance military medical capabilities by funding innovative research addressing critical areas such as trauma care, brain health, casualty management, and human performance optimization, with individual project budgets ranging from $700,000 to $5 million. The research funded under this BAA is intended to benefit both military and civilian medical practices, emphasizing the importance of applicable solutions for unique operational environments. Interested organizations, including non-profits and educational institutions, must submit a pre-proposal via the electronic Biomedical Research Application Portal (eBRAP) before being invited to submit a full proposal through Grants.gov, with a total annual funding budget of $10 million available for selected projects. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or Jessee Chege at jessee.t.chege.civ@health.mil.
    BROAD AGENCY ANNOUNCEMENT - BIOMEDICAL RESEARCH AND DIVING EQUIPMENT DEVELOPMENT
    Dept Of Defense
    The Department of Defense, specifically the Naval Sea Systems Command (NAVSEA), is soliciting proposals through a Broad Agency Announcement (BAA) for biomedical research and diving equipment development aimed at enhancing diver health, safety, and performance, as well as submarine escape and rescue capabilities. The primary objectives include improving diving equipment and biomedical aspects related to diver operations, with a focus on areas such as breathing gas supply, human performance, environmental protection, decompression, and submarine rescue strategies. This initiative is critical for advancing the safety and effectiveness of Navy personnel during underwater operations, with contracts typically averaging around $300,000 annually. Interested parties must submit pre-proposals by November 30, 2024, for FY26 funding, with full proposals due by February 28, 2025. For further inquiries, contact Lisa Grayum at lisa.m.grayum.civ@us.navy.mil or Daniel Kough at daniel.w.kough2.civ@us.navy.mil.
    Research and Development Innovations Broad Agency Announcement
    Dept Of Defense
    The Defense Threat Reduction Agency (DTRA) is soliciting innovative research and development proposals through its Broad Agency Announcement (BAA) HDTRA1-22-S-0003, aimed at countering weapons of mass destruction (WMD) and emerging threats. The BAA invites proposals for technologies at Technology Readiness Levels (TRL) 1-7, focusing on five key thrust areas: understanding WMD threats, enabling deterrence, controlling and defeating threats, protecting forces, and cross-cutting capabilities. This multi-year solicitation, active from February 2022 to February 2027, anticipates contract awards ranging from $500,000 to $5,000,000 over 1-3 years, with a two-phased proposal process. Interested parties should direct inquiries to the BAA Program Manager at dtra.belvoir.rd.mbx.rd-baa-inbox@mail.mil, and adhere to submission deadlines, including a final proposal submission date of September 19, 2025, for the latest addendum.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    Inflammatory and Vascular Diseases Scientific Support
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a contract for Inflammatory and Vascular Diseases Scientific Support to Exonova Biosciences. The procurement aims to secure the services of a highly qualified scientist with extensive expertise in immunology and hereditary autoinflammatory diseases, who will contribute to the NIH's Biomedical and Metabolic Imaging Branch's research initiatives. This contract is crucial for advancing understanding in the fields of inflammation and vascular biology, particularly in relation to metabolic disorders, and is set to commence on January 1, 2026, with a performance period extending through December 31, 2026. Interested parties must respond by December 15, 2025, and can direct inquiries to Kimesha Leake at Kimesha.leake@nih.gov.